DexCom (DXCM) Rating Lowered to Sell at ValuEngine

DexCom (NASDAQ:DXCM) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Several other research analysts have also commented on DXCM. Barclays reaffirmed a “hold” rating and issued a $60.00 price target on shares of DexCom in a report on Monday, January 8th. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Northland Securities reissued a “hold” rating and set a $50.00 target price on shares of DexCom in a research note on Thursday, November 2nd. BMO Capital Markets boosted their target price on shares of DexCom to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Finally, Jefferies Group boosted their target price on shares of DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $68.50.

DexCom (NASDAQ DXCM) opened at $54.35 on Thursday. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other news, EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total transaction of $660,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,140 shares of company stock valued at $2,743,281. Company insiders own 1.70% of the company’s stock.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after acquiring an additional 354 shares during the period. Advisor Group Inc. raised its holdings in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares in the last quarter. Wedbush Securities Inc. raised its holdings in shares of DexCom by 24.2% in the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after purchasing an additional 1,089 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of DexCom by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock worth $6,247,000 after purchasing an additional 1,095 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of DexCom by 15.2% in the 3rd quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock worth $422,000 after purchasing an additional 1,129 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/10/dexcom-dxcm-rating-lowered-to-sell-at-valuengine.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply